Technologies

Medical Sciences

Title:	Novel Cationic 17-Estradiol-Substituted-Estradiol Derivatives with Anti-cancer Activity
Area:	Medical Sciences
Focus Area:	Cancer Treatment
Patent:	EP2111409, IN263345, JP5276020, US8012952
Social Benefits:	These Estrogen-structure based molecules have the ability to kill cancer cells of all stages of breast cancer. Other existing estrogen-based or estrogenic anticancer molecule acts against estrogen receptor (ER)-expressing breast cancer cells only. So, this molecule is 'fit-for-all' breast cancerphenotypes, These molecules have anticancer effect against other ER-expressing cancer cells, such as ovarian carcinoma, melanoma, pancreatic cancer, It is orally administrable (whereas estrogenic, anti-breast cancer drug FaslodexTM is intramuscularly injectable only). Hence, it holds the promise to become the first oral breast cancerdrug developed from India
Developing Agency:	CSIR-Indian Institute of Chemical Technology (IICT), Telangana
Technology Readiness Index:	Lab Validation
Email:	director@iict.res.in
Website Link :	http://www.iictindia.org
Source (more info) :	https://t.ly/l_sb

Brief Description

Description :

Tested preclinically in triple negative breast tumor animal model (the most aggressive breast cancer model). The molecule is co-formulated in liposomes and developed further in association with Mayo Clinic, USA for treating multiple other aggressive cancers such as melanoma, pancreatic cancer.